Matrix Capital Management Company, LP

This profile gathers the share dealings of Matrix Capital Management Company, LP across 2 companies, led by Aura Biosciences, Inc. and Zentalis Pharmaceuticals, Inc. We count 6 filings; the first trade dates from 2 November 2021 and the latest from 15 December 2025.

On the open market, the record shows 4 purchases worth €147.6M and 1 sale worth €8.5M. On balance, insiders were net buyers of €139.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2025: no purchases and 1 sale on the market.

In size, the median ticket on the buying side is €17.9M. 2 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 15 December 2025 with an open-market sale (€8.5M) in Zentalis Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,080 days ago, on 9 November 2023. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.